Skip to main content

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s Form 4 filing

Natures Sunshine Products Inc (NATR) · filed Oct 15, 2024

Accession no.
0001104659-24-108390
Filed
Oct 15, 2024
Trade date
Sep 6-Oct 14, 2024
Filing delay
39 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 7 non-derivative transactions. Open-market sales total $145.2K. It was filed 39 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.CIK 000161525810% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 6, 2024Common StockJOtherAcquired+2,968$0.00$077,362Indirect
Oct 1, 2024Common StockSSaleDisposed−1,399$13.54−$18,942.4675,963Indirect
Oct 8, 2024Common StockSSaleDisposed−1,800$13.13−$23,63474,163Indirect
Oct 9, 2024Common StockSSaleDisposed−1,816$13.36−$24,261.7672,347Indirect
Oct 10, 2024Common StockSSaleDisposed−3,000$13.39−$40,17069,347Indirect
Oct 11, 2024Common StockSSaleDisposed−1,580$13.37−$21,124.667,767Indirect
Oct 14, 2024Common StockSSaleDisposed−1,300$13.12−$17,05666,467Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)